The newborn screening market size is projected to reach US$ 2,484.16 million by 2030 from US$ 1,206.74 million in 2022. The market is expected to register a CAGR of 9.40% during 2022–2030. Integration of machine learning and artificial intelligence (AI) in screening will likely remain a key trend in the market.
The market is expected to grow due to increased public and healthcare provider awareness of the value of early diagnosis and intervention for newborn disorders through government and nonprofit educational campaigns. Moreover, the need for newborn screening is boosted by increased birth rates, especially in developing nations. Stakeholders in the newborn screening market can improve early detection and intervention and, eventually, improve the health outcomes of newborns globally by utilizing these drivers and opportunities.
Governments of different countries are increasingly allocating funds for newborn screening programs. These programs help reduce long-term healthcare costs for children and their parents, as congenital and genetic disorders could result in severe health complications and extensive medical interventions if left undetected. By identifying and addressing health issues in infancy, governments can enhance the health and well-being of their citizens. Thus, newborn screening aligns with broader public health objectives to improve overall population health and reduce the burden on healthcare systems.
Government funding promotes equity in healthcare access, ensuring that newborn screening services are available to all, regardless of socioeconomic status. This inclusivity is essential for early disease detection and intervention, as it prevents disparities in healthcare outcomes among different demographic groups. As governments continue prioritizing newborn screening through increased funding and policy support, the infant screening market has been experiencing sustainable growth worldwide.
Congenital diseases can lead to lifelong health challenges if not detected and managed early. These diseases can contribute to long-term disability, significantly affecting families, individuals, healthcare systems, and societies. The WHO estimates that 240,000 newborns worldwide succumb to death each year within 28 days of birth due to these diseases. An additional 170,000 children die between the ages of 1 month and five years due to congenital diseases. A growing understanding of the genetic basis of many congenital diseases is one of the several factors contributing to the increasing burden of these conditions. Genomics and genetic testing advancements have enabled healthcare providers to identify a broader range of genetic mutations and conditions in newborns. This expanded knowledge has highlighted the importance of early diagnosis through newborn screening to initiate timely interventions and treatments.
Changing demographics such as maternal age, environmental exposures, and altering lifestyle habits increase the risk of congenital conditions in newborns. Moreover, the number of births occurring every day is on the rise due to the burgeoning global population, resulting in an expanding pool of infants that can be at risk of congenital diseases. In addition, healthcare systems and policymakers recognize the long-term benefits of early disease detection. They increasingly incorporate newborn screening into routine healthcare protocols and insurance coverage, further stimulating market growth. The rising burden of congenital diseases is a significant driver behind the development of the newborn screening market.
The demand for comprehensive genetic screening of newborns is rising with the deepening knowledge about the genetic causes of medical conditions and advancements in healthcare technologies. As a result, companies in the newborn screening market are developing innovative, cost-effective screening solutions. The US FDA licensed the Kymriah gene therapy in 2017 for use in pediatric patients with a particular kind of acute lymphoblastic leukemia. During this therapy, a new gene that codes for a chimeric antigen receptor is inserted into the patient's T cells, stimulating the altered T cells to go after and destroy the leukemic cells. Yescarta and Zynteglo are two more examples of authorized gene treatments for large B-cell lymphoma and beta-thalassemia. Further, the emergence of technologies conferring an ability to identify genetic predispositions to diseases at birth paved the way for personalized healthcare, aligning with the broader trend of precision medicine.
Screening for genetic diseases during pregnancy also focuses on the early detection of pregnancy-related problems. Next-generation sequencing aids in the prenatal screening of neonates with a sensitivity above 95% for detecting aneuploidies (such as Down syndrome and Trisomy 21) or partial chromosomal abnormalities (duplications or deletions) in all chromosomes. Fluorescence in-situ hybridization (FISH) is employed to detect monogenic illnesses such as sickle cell anemia and aids in an effective preimplantation genetic diagnosis. Recent advancements in genetic tests include non-invasive procedures such as the cell-free fetal DNA approach using maternal plasma. The embryonic DNA can be distinguished from maternal DNA pieces based on size differences. Real-time PCR with fluorescent probes, shotgun sequencing (Solexa or Illumina), or massive targeted parallel sequencing can be used to examine DNA associated with fetal medical conditions. This will allow doctors to provide early molecular interventions with specific pharmacological therapies (pharmacogenetics) and transform cells, tissues, and organs physically and chemically if this genetic screening is further researched. Thus, advancements in methods for screening infants for genetic disorders hold immense potential for the overall newborn screening market.
Key segments that contributed to the derivation of the newborn screening market analysis are product type, technology, test type, and end user.
The geographic scope of the newborn screening market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
The newborn screening market in North America has experienced significant growth in recent years. The demand for newborn screening services has increased significantly with the surging awareness among parents and healthcare professionals about the importance of early screening for identifying and managing congenital disorders. Additionally, improvements in medical technology have been crucial in enhancing newborn screening capabilities—laboratory automation has boosted screening accuracy, speed, and cost-effectiveness. This has made it possible for medical professionals to give thorough newborn screening panels that cover a larger spectrum of genetic and metabolic disorders. Favorable legislation and regulatory measures also benefit the newborn screening market in North America. Many states and provinces have implemented mandatory newborn screening programs, ensuring all infants are screened shortly after birth. For instance, every state in the US offers newborn screening as a public health program; yearly, ~4 million babies are screened under this program for illnesses that aren't often present at the time of delivery. The Texas Department of Health and Human Services began screening newborns for Spinal Muscular Atrophy (SMA) in June 2021.
The rising prevalence of genetic abnormalities and congenital problems has highlighted the significance of newborn screening. The National Institutes of Health has given a researcher from the University at Buffalo a highly competitive R01 grant to lead an international project to significantly increase the accuracy of newborn screening for three rare, frequently fatal genetic diseases.
Further, the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH funds the US$ 3.8 million five-year award. Thus, the newborn screening market in North America is increasing with increased awareness, technological advancements, supportive policies, and the growing prevalence of congenital disorders.
The regional trends and factors influencing the Newborn Screening Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Newborn Screening Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,206.74 Million |
| Market Size by 2030 | US$ 2,484.16 Million |
| Global CAGR (2022 - 2030) | 9.40% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Newborn Screening Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Newborn Screening Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The newborn screening market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the newborn screening market are listed below:
The “Newborn Screening Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
The List of Companies - Newborn Screening Market
North America dominated the newborn screening market in 2022
Key factors driving the market are the increasing burden of congenital diseases leading to an increase in demand for newborn screening and surging government funding for newborn screening.
Integration of machine learning and artificial intelligence (AI) in screening will likely remain a key trend in the market.
LifeCell International Pvt Ltd, Zentech SA, Trivitron Healthcare Pvt Ltd, PerkinElmer Inc, Waters Corp, Bio-Rad Laboratories Inc., Masimo Corp, Natus Medical Inc., Baebies Inc, MRC Holland BV, Medtronic Plc
The market is expected to register a CAGR of 9.40% during 2022–2030.